Payment overview · 2025
General Payments
$2,257.65
99 reported records · 22 companies
Healthcare provider profile · identity verified
Rahul Patri, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · BEAUMONT, TX · NPI 1578720850
Verified facts
What the public records show
CMS Open Payments records show Rahul Patri, MD received $2,257.65 in general payments during 2025 across 99 reported records.
Abbott Laboratories accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Camzyos, Eliquis, Entresto, Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAMZYOS as an associated drug or biological on 41009 records involving 16400 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Camzyos by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 924 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 924 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $651.60 | 28.9% | 4 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $278.66 | 12.3% | 22 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $220.67 | 9.8% | 13 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $140.18 | 6.2% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.29 | 5.0% | 6 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $106.14 | 4.7% | 7 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $105.89 | 4.7% | 3 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $79.44 | 3.5% | 4 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $77.00 | 3.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $69.19 | 3.1% | 4 | 2025 |
| Cleerly, Inc. | Unresolved — no canonical attribution shown | $59.59 | 2.6% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $54.44 | 2.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $45.99 | 2.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.28 | 1.8% | 2 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $40.20 | 1.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $37.18 | 1.6% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $32.66 | 1.4% | 3 | 2025 |
| ENDOTRONIX, INC. | Unresolved — no canonical attribution shown | $27.76 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.74 | 1.2% | 2 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $18.33 | 0.8% | 1 | 2025 |
| Cagent Vascular INC | Unresolved — no canonical attribution shown | $16.42 | 0.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$15.00 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,606.05 | 95 |
| Travel and Lodging | $651.60 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $651.60 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $278.66 | 22 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $204.95 | 12 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $140.18 | 12 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $105.89 | 3 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $79.44 | 4 | 2025 |
Source payment records
|
|||||
| Cleerly Ischemia Normalized: cleerly ischemia |
Device | Cleerly, Inc. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| Cleerly Labs Normalized: cleerly labs |
Device | Cleerly, Inc. | $59.59 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $54.44 | 2 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $54.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $49.38 | 3 | 2025 |
Source payment records
|
|||||
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $48.01 | 2 | 2025 |
Source payment records
|
|||||
| ACUITY Steerable Normalized: acuity steerable |
Device | Boston Scientific Corporation | $47.21 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $45.99 | 2 | 2025 |
Source payment records
|
|||||
| SURGIFLO Hemostatic Matrix Normalized: surgiflo hemostatic matrix |
Device | Ethicon US, LLC | $40.20 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $37.24 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $32.66 | 3 | 2025 |
Source payment records
|
|||||
| CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Normalized: cordella pulomonary artery pressure sensor |
Device | ENDOTRONIX, INC. | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $27.74 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $25.53 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY+ Normalized: ingevity |
Device | Boston Scientific Corporation | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| General - Brady Normalized: general brady |
Device | Boston Scientific Corporation | $21.76 | 2 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| OUTBACK Normalized: outback |
Device | CORDIS US CORP. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| ANGIOGUARD Normalized: angioguard |
Device | CORDIS US CORP. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Hillrom - Carnation Ambulatory Monitor Normalized: hillrom carnation ambulatory monitor |
Device | Baxter Healthcare | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| Serrantor Normalized: serrantor |
Device | Cagent Vascular INC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| ZOOM Wireless Transmitter Normalized: zoom wireless transmitter |
Device | Boston Scientific Corporation | $14.37 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $12.28 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $11.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAMZYOS camzyos |
2025 | Camzyos | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 924 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 179 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 140 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
86 | 21 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
140 | 32 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | CAMZYOS open payments reported associated product |
CMS Open Payments — General Payments 41009 supporting records · 16400 recipient NPIs · example record 1184377697 |
Camzyos · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
924 | 196 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
179 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
924 | 196 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Metoprolol Succinate | Metoprolol Succinate | 1168 | 306 |
| Eliquis | Apixaban | 924 | 196 |
| Losartan Potassium | Losartan Potassium | 786 | 208 |
| Carvedilol | Carvedilol | 636 | 179 |
| Clopidogrel | Clopidogrel Bisulfate | 592 | 158 |
| Furosemide | Furosemide | 574 | 177 |
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 488 | 140 |
| Hydrochlorothiazide | Hydrochlorothiazide | 411 | 115 |
| Lisinopril | Lisinopril | 274 | 80 |
| Amiodarone Hcl | Amiodarone Hcl | 251 | 84 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 182 | 47 |
| Entresto | Sacubitril/Valsartan | 179 | 32 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 49 |
| Xarelto | Rivaroxaban | 162 | 28 |
| Cilostazol | Cilostazol | 154 | 39 |
| Sotalol | Sotalol Hcl | 152 | 38 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 47 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 142 | 45 |
| Farxiga | Dapagliflozin Propanediol | 140 | 32 |
| Potassium Chloride | Potassium Chloride | 114 | 36 |
| Pravastatin Sodium | Pravastatin Sodium | 110 | 32 |
| Warfarin Sodium | Warfarin Sodium | 108 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 105 | 30 |
| Flecainide Acetate | Flecainide Acetate | 101 | 26 |
| Ezetimibe | Ezetimibe | 87 | 26 |
| Brilinta | Ticagrelor | 86 | 21 |
| Clonidine Hcl | Clonidine Hcl | 80 | 29 |
| Nifedipine Er | Nifedipine | 79 | 25 |
| Ranolazine Er | Ranolazine | 77 | 15 |
| Bumetanide | Bumetanide | 69 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 18 |
| Nitroglycerin | Nitroglycerin | 53 | 40 |
| Enoxaparin Sodium | Enoxaparin Sodium | 50 | 38 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 49 | 18 |
| Valsartan | Valsartan | 45 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 13 |
| Digoxin | Digoxin | 40 | 12 |
| Fenofibrate | Fenofibrate | 40 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Simvastatin | Simvastatin | 36 | 13 |
| Irbesartan | Irbesartan | 32 | suppressed |
| Spironolactone | Spironolactone | 30 | 12 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Jardiance | Empagliflozin | 21 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Camzyos | Mavacamten | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Droxidopa | Droxidopa | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,257.65 · 99 records | Abbott Laboratories | ACUITY Steerable, ANGIOGUARD, AURYON LASER SYSTEM 100-120 VAC, AVEIR, Assure WCD, CAMZYOS, CORDELLA PULOMONARY ARTERY PRESSURE SENSOR, Cleerly Ischemia, Cleerly Labs, ELIQUIS, ENTRESTO, FARAPULSE, FARXIGA, General - Brady, General - EP, Hillrom - Carnation Ambulatory Monitor, INGEVITY MRI, INGEVITY+, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, MICRA, MYNX CONTROL, NEXLETOL, OPSUMIT, OUTBACK, REPATHA, SURGIFLO Hemostatic Matrix, Serrantor, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, UPTRAVI, VERQUVO, WAINUA, WATCHMAN FLX, ZOOM Wireless Transmitter | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Camzyos play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error